专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2015061302A1 INTRA-AMNIOTIC ADMINISTRATION OF PROTEINS FOR THE TREATMENT OF ECTODERMAL DYSPLASIAS 审中-公开
标题翻译：用于治疗ECTODERMAL DYSPLASIAS的蛋白质的内在管理
公开(公告)号：WO2015061302A1
公开(公告)日：2015-04-30
申请号：PCT/US2014/061550
申请日：2014-10-21
申请人： EDIMER PHARMACEUTICALS, INC. , FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG
发明人： SCHNEIDER, Pascal , HUTTNER, Kenneth, M. , KIRBY, Neil , SCHNEIDER, Holm
IPC分类号： A61K39/00 , A61K38/00
CPC分类号： A61K9/0034 , A61K38/17 , A61K38/191
摘要： The disclosure relates to methods for the intra-amniotic administration of ectodysplasin A (EDA) agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, X-linked hypohidrotic ectodermal dysplasia (XLHED).
摘要翻译：本公开涉及羊膜内施用异位体积A（EDA）激动剂，特别是EDI200的方法。使用所描述的方法允许设计靶向治疗剂量和给药方案，以便校正或改变与外胚层发育不良相关的异常表型，特别是X连锁的hypohidrotic外胚层发育不良（XLHED）。

22. 发明专利

AU2012256174B2 Compositions and methods for the alteration of XLHED phenotypes 未知
公开(公告)号：AU2012256174B2
公开(公告)日：2016-10-27
申请号：AU2012256174
申请日：2012-05-10
申请人： EDIMER PHARMACEUTICALS INC
发明人： SCHNEIDER PASCAL , KOWALCZYK CHRISTINE
IPC分类号： C07K16/00 , C07K17/00 , C07K17/14 , C12P21/08
摘要： The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

23. 发明专利

IL229015D0 Compositions and methods for the alteration of xlhed phenotypes 未知
公开(公告)号：IL229015D0
公开(公告)日：2013-12-31
申请号：IL22901513
申请日：2013-10-22
申请人： EDIMER PHARMACEUTICALS INC
IPC分类号： C07K20060101
摘要： The invention relates to methods for the temporal administration ofEDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

24. 发明专利

BR112013029331A2 composições e métodos para a alteração dos fenótipos xlhed 未知
公开(公告)号：BR112013029331A2
公开(公告)日：2017-12-19
申请号：BR112013029331
申请日：2012-05-10
申请人： EDIMER PHARMACEUTICALS INC
发明人： CHRISTINE KOWALCZYK , PASCAL SCHNEIDER
IPC分类号： C07K16/00 , C07K17/00 , C07K17/14 , C12P21/08

25. 发明专利

AU2013344973B2 Compositions and methods for the treatment of ectodermal dysplasia 未知
公开(公告)号：AU2013344973B2
公开(公告)日：2016-10-06
申请号：AU2013344973
申请日：2013-11-13
申请人： EDIMER PHARMACEUTICALS INC
发明人： HUTTNER KENNETH M , KIRBY NEIL , SCHNEIDER PASCAL , GAIDE OLIVIER
IPC分类号： C12P21/00 , A61K38/19
摘要： The invention relates to pharmaceutical compositions and methods for the treatment of ectodermal displasias via the administration of EDA agonists, in particular EDI200. Use of the compositions and methods described allow for therapeutic dosing and administration regimens in human patients to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

26. 发明专利

NZ616824A Compositions and methods for the alteration of xlhed phenotypes 未知
公开(公告)号：NZ616824A
公开(公告)日：2015-12-24
申请号：NZ61682412
申请日：2012-05-10
申请人： EDIMER PHARMACEUTICALS INC
发明人： SCHNEIDER PASCAL , KOWALCZYK CHRISTINE
IPC分类号： C07K16/00 , A61K38/16 , C07K14/705 , C07K17/00
摘要： Disclosed is a protein comprising the amino acid sequence represented by SEQ ID NO: 1, wherein SEQ ID NO: 1 is disclosed within the specification. The protein of SEQ ID NO: 1 is a fully humanised Fc fusion protein consisting of the Fc region of human IgG1 and the receptor binding domain (Tumour Necrosis Factor (TNF) domain) of EDA-A1. Also disclosed is the use of such a protein in the manufacture of a medicament for correcting, altering or mitigating a phenotypic presentation associated with ectodermal dysplasia.

27. 发明专利

AR093476A1 COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LA DISPLASIA ECTODERMICA 未知
公开(公告)号：AR093476A1
公开(公告)日：2015-06-10
申请号：ARP130104180
申请日：2013-11-13
申请人： EDIMER PHARMACEUTICALS INC
发明人： KENNETH M HUTTNER , NEIL KIRBY , PASCAL SCHNEIDER , OLIVIER GAIDE
IPC分类号： A61K38/16
摘要： Composiciones farmacéuticas y métodos para el tratamiento de displasias ectodérmicas mediante la administración de agonistas de EDA (displasia ectodérmica anhidrótica), en particular EDI200. El uso de las composiciones y métodos descritos permite la dosificación terapéutica y regímenes de administración en pacientes humanos para corregir o alterar los fenotipos anormales asociadas con trastornos genéticos, en particular, XLHED (displasia ectodérmica hipodrótica ligada al X). Reivindicación 1: Una composición farmacéutica caracterizada porque comprende al menos un monómero proteico, en donde dicho monómero proteico comprende SEQ ID Nº 1 y en donde dicho al menos un monómero proteico está glicosilado en las posiciones Asn76 y Asn302, y un excipiente farmacéuticamente aceptable. Reivindicación 6: La composición farmacéutica de la reivindicación 1, caracterizada porque el excipiente farmacéuticamente aceptable es un diluyente que comprende fosfato de sodio y cloruro de sodio. Reivindicación 7: La composición farmacéutica de la reivindicación 6, caracterizada porque además comprende uno o más tensioactivos y/o detergentes. Reivindicación 8: La composición farmacéutica de la reivindicación 7, caracterizada porque además comprende polisorbato 20.

28. 发明专利

AU2013344973A1 Compositions and methods for the treatment of ectodermal dysplasia 未知
公开(公告)号：AU2013344973A1
公开(公告)日：2015-05-14
申请号：AU2013344973
申请日：2013-11-13
申请人： EDIMER PHARMACEUTICALS INC
发明人： HUTTNER KENNETH M , KIRBY NEIL , SCHNEIDER PASCAL , GAIDE OLIVIER
IPC分类号： C12P21/00 , A61K38/19
摘要： The invention relates to pharmaceutical compositions and methods for the treatment of ectodermal displasias via the administration of EDA agonists, in particular EDI200. Use of the compositions and methods described allow for therapeutic dosing and administration regimens in human patients to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

29. 发明专利

CA2891386A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA 未知
公开(公告)号：CA2891386A1
公开(公告)日：2014-05-22
申请号：CA2891386
申请日：2013-11-13
申请人： EDIMER PHARMACEUTICALS INC
发明人： HUTTNER KENNETH M , KIRBY NEIL , SCHNEIDER PASCAL , GAIDE OLIVIER
IPC分类号： C12P21/00 , A61K38/19 , C07K14/525 , C07K19/00
摘要： The invention relates to pharmaceutical compositions and methods for the treatment of ectodermal displasias via the administration of EDA agonists, in particular EDI200. Use of the compositions and methods described allow for therapeutic dosing and administration regimens in human patients to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

30. 发明专利

ZA201407978B COMPOSITIONS AND METHODS FOR THE ALTERATION OF XLHED PHENOTYPES 未知
公开(公告)号：ZA201407978B
公开(公告)日：2016-05-25
申请号：ZA201407978
申请日：2014-10-31
申请人： EDIMER PHARMACEUTICALS INC
发明人： KOWALCZYK CHRISTINE , SCHNEIDER PASCAL
摘要： The invention relates to methods for the temporal administration ofEDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式